SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes
Status:
Terminated
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the good and bad effects of an experimental drug called
SF1126. This drug is being tested in patients whose cancer has not been controlled by
available standard therapies and who have certain genes in their tumor.
SF1126 is a drug that inhibits a cell protein called phosphatidyl inositol 3 kinase (PI3K).
PI3K is part of signaling pathway that tells cancer cells to grow, survive, invade and
metastasize. PI3K also has an important role in the development of blood vessels that are
required to support tumor growth. SF1126 is being developed by SignalRx Pharmaceuticals, Inc.
It is considered an experimental drug because it is not approved by the FDA for any disease
treatment.